Dogwood Therapeutics公司近日宣布成功获得高达2680万美元的融资支持,该笔资金将专项用于推进其核心候选药物Halneuron®完成二期临床试验B阶段的研究工作。此次融资将为Halneuron®的临床开发计划提供关键资源保障,标志着该创新疗法在神经疾病治疗领域迈出重要一步。
Dogwood Therapeutics公司近日宣布成功获得高达2680万美元的融资支持,该笔资金将专项用于推进其核心候选药物Halneuron®完成二期临床试验B阶段的研究工作。此次融资将为Halneuron®的临床开发计划提供关键资源保障,标志着该创新疗法在神经疾病治疗领域迈出重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.